Ayşe Nur Bayındır Akbaş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayşe Nur Bayındır Akbaş has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Bünyamin Kısacık
Department of Rheumatology, Sanko University Medical Faculty Hospital, 16049 Gaziantep, Turkey
4 shared publications - Dilek Tezcan
Department of Rheumatology, Gülhane Training and Research Hospital, Ankara, Turkiye
4 shared publications - Fatih Albayrak
Department of Rheumatology, Gaziantep University, 27310 Gaziantep, Turkey
4 shared publications - Burcu Yağız
Division of Rheumatology, Faculty of Medicine, Uludag University, Bursa 16059, Turkey
3 shared publications - Elif Gur Kabul
Usak University
3 shared publications - Elif İnanç
Department of Internal Medicine Division of Rheumatology İnönü University Faculty of Medicine Malatya Türkiye
3 shared publications
Latest Publications
- 23 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7391-7399
Clinical characteristics of persistent ısotretinoin-associated ınflammatory back pain: a retrospective cohort study
- 23 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7391-7399
Clinical characteristics of persistent ısotretinoin-associated ınflammatory back pain: a retrospective cohort study
- 20 August 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (6) , 447-457
Factors associated with shorter time to death and causes of mortality among deceased patients with systemic sclerosis: a multicentre retrospective study
Systemic sclerosis (SSc), also known as scleroderma, is a rare and complex autoimmune connective tissue disease. It is characterized by progressive fibrosis, vascular abnormalities, and severe comp...
- 20 August 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (6) , 447-457
Factors associated with shorter time to death and causes of mortality among deceased patients with systemic sclerosis: a multicentre retrospective study
Systemic sclerosis (SSc), also known as scleroderma, is a rare and complex autoimmune connective tissue disease. It is characterized by progressive fibrosis, vascular abnormalities, and severe comp...
- 2 April 2026
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 68 (10) , 841-847
Examination of Work Performance of Patients With Rheumatoid Arthritis
Objective: The aim was to investigate the factors affecting and associated with work performance of rheumatoid arthritis (RA) patients. Methods: Fifty RA were included. Results: The average annual disease leave was 4.16±8.77 days. 12% of patients changed works due to disease, 32% reduced working hours, 20% quit works. Arthritis Work Spillover Scale had low correlation with Disease Activity Score-28, ABILHAND-RA questionnaire, Biopsychosocial Questionnaire, St. George's Respiratory Questionnaire-Activity, Short Form-36-Mental, Unsupported Upper-Limb Exercise Test-duration and level, maximal inspiratory pressure, maximal expiratory pressure (r:0.282-r:0.453) and had moderate correlation with Visual Analog Scale-General Pain, Health Assessment Questionnaire, Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), DASH-W, Short Form-36-Physical (r:0.516-r:-0.687)(p Export
- 2 April 2026
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 68 (10) , 841-847
Examination of Work Performance of Patients With Rheumatoid Arthritis
Objective: The aim was to investigate the factors affecting and associated with work performance of rheumatoid arthritis (RA) patients. Methods: Fifty RA were included. Results: The average annual disease leave was 4.16±8.77 days. 12% of patients changed works due to disease, 32% reduced working hours, 20% quit works. Arthritis Work Spillover Scale had low correlation with Disease Activity Score-28, ABILHAND-RA questionnaire, Biopsychosocial Questionnaire, St. George's Respiratory Questionnaire-Activity, Short Form-36-Mental, Unsupported Upper-Limb Exercise Test-duration and level, maximal inspiratory pressure, maximal expiratory pressure (r:0.282-r:0.453) and had moderate correlation with Visual Analog Scale-General Pain, Health Assessment Questionnaire, Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), DASH-W, Short Form-36-Physical (r:0.516-r:-0.687)(p Export
- 23 September 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108354
Problem analysis based on the international classification of functioning, disability and health (ICF) in patients with Takayasu arteritis
- 23 September 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108354
Problem analysis based on the international classification of functioning, disability and health (ICF) in patients with Takayasu arteritis
- Open Access
- 22 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5181
Evaluating Secukinumab as Treatment for Axial Spondyloarthritis and Psoriatic Arthritis in Patients with Comorbidities: Multicenter Real-Life Experience
Background: Secukinumab is a fully human monoclonal antibody that targets interleukin (IL)-17A and is used to treat axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Treating axSpA and PsA can be challenging in patients with comorbidities. In this multicenter retrospective study, we aimed to evaluate the efficacy and safety of secukinumab treatment in patients with axSpA and PsA who had a history of tuberculosis, multiple sclerosis (MS), or congestive heart failure (CHF). Methods: The study included 44 patients with a diagnosis of axSpA and PsA and a history of tuberculosis, MS, or CHF who received secukinumab treatment at 13 centers in our country. Erythrocyte sedimentation rate, C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score CRP, visual analog scale, and Disease Activity Score-28 CRP markers at months 0, 3, and 12 of secukinumab treatment were analyzed. Alongside this, tuberculosis, MS, and CHF were evaluated at follow-up using clinical assessments and imaging methods such as chest radiographs, brain magnetic resonance, and echocardiography. Results: A statistically significant improvement in inflammatory markers and disease activity scores was observed in patients treated with secukinumab. There was no reactivation in patients with a history of tuberculosis. In most MS patients, the disease was stable, while clinical and radiological improvement was observed in one patient. No worsening of CHF stage was observed in patients with a history of CHF. Conclusions: With regular clinical monitoring, secukinumab may be an effective and safe treatment option for axSpA and PsA patients with a history of tuberculosis, MS, or CHF.
- 22 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5181
Open AccessEvaluating Secukinumab as Treatment for Axial Spondyloarthritis and Psoriatic Arthritis in Patients with Comorbidities: Multicenter Real-Life Experience
Background: Secukinumab is a fully human monoclonal antibody that targets interleukin (IL)-17A and is used to treat axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Treating axSpA and PsA can be challenging in patients with comorbidities. In this multicenter retrospective study, we aimed to evaluate the efficacy and safety of secukinumab treatment in patients with axSpA and PsA who had a history of tuberculosis, multiple sclerosis (MS), or congestive heart failure (CHF). Methods: The study included 44 patients with a diagnosis of axSpA and PsA and a history of tuberculosis, MS, or CHF who received secukinumab treatment at 13 centers in our country. Erythrocyte sedimentation rate, C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score CRP, visual analog scale, and Disease Activity Score-28 CRP markers at months 0, 3, and 12 of secukinumab treatment were analyzed. Alongside this, tuberculosis, MS, and CHF were evaluated at follow-up using clinical assessments and imaging methods such as chest radiographs, brain magnetic resonance, and echocardiography. Results: A statistically significant improvement in inflammatory markers and disease activity scores was observed in patients treated with secukinumab. There was no reactivation in patients with a history of tuberculosis. In most MS patients, the disease was stable, while clinical and radiological improvement was observed in one patient. No worsening of CHF stage was observed in patients with a history of CHF. Conclusions: With regular clinical monitoring, secukinumab may be an effective and safe treatment option for axSpA and PsA patients with a history of tuberculosis, MS, or CHF.
- Open Access
- 18 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6216
Secukinumab May Be an Effective Treatment Option for Axial Spondyloarthritis and Psoriatic Arthritis Patients with a History of Malignancy: Multicenter Real-Life Experience from Turkey
Background: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited. This study aimed to investigate the drug’s survival time and the efficacy and safety of secukinumab treatment in this specific patient group. Methods: This retrospective study included 30 patients with a history of malignancy who were followed up in rheumatology outpatient clinics in 12 centers throughout Turkey and treated with secukinumab between May 2018 and March 2024 with a diagnosis of axSpA and PsA. Results: The mean follow-up time was 29.8 ± 19.3 months. The drug retention rate was 89.7% after 12 months and 80.6% after 24 months. The most common tumor in our study was papillary thyroid carcinoma (n = 5, 16.7%). During follow-up, local tumor recurrence was observed in a patient with urothelial carcinoma of the bladder. Conclusions: In the largest cohort reported to date, treatment with secukinumab in axSpA and PsA patients with a history of malignancy was not shown to cause oncologic recurrence except for one local tumor recurrence. Drug retention rates were also high, and disease activation and function improved compared to baseline. Therefore, secukinumab could be a safe and effective option for this patient group.
- 18 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6216
Open AccessSecukinumab May Be an Effective Treatment Option for Axial Spondyloarthritis and Psoriatic Arthritis Patients with a History of Malignancy: Multicenter Real-Life Experience from Turkey
Background: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited. This study aimed to investigate the drug’s survival time and the efficacy and safety of secukinumab treatment in this specific patient group. Methods: This retrospective study included 30 patients with a history of malignancy who were followed up in rheumatology outpatient clinics in 12 centers throughout Turkey and treated with secukinumab between May 2018 and March 2024 with a diagnosis of axSpA and PsA. Results: The mean follow-up time was 29.8 ± 19.3 months. The drug retention rate was 89.7% after 12 months and 80.6% after 24 months. The most common tumor in our study was papillary thyroid carcinoma (n = 5, 16.7%). During follow-up, local tumor recurrence was observed in a patient with urothelial carcinoma of the bladder. Conclusions: In the largest cohort reported to date, treatment with secukinumab in axSpA and PsA patients with a history of malignancy was not shown to cause oncologic recurrence except for one local tumor recurrence. Drug retention rates were also high, and disease activation and function improved compared to baseline. Therefore, secukinumab could be a safe and effective option for this patient group.
- Open Access
- 31 August 2023
- Published by Bulent Evcevit University in Turkish Journal of Diabetes and Obesity
- Vol. 7 (2) , 175-181
Investigation of Body Compositions and Dietary Habits of Patients with Rheumatoid Arthritis: A Case Control Study
Aim: The aim of this study was to investigate the body composition and dietary habits of patients with Rheumatoid Arthritis (RA) and to compare them with healthy controls. Material and Methods: 64 participants (RA n=32 and mean age: 55.2±1.5 years; Healthy Group n=32 and mean age: 54.5±1.5 years) were included in the study. Body compositions (body mass index, body fat ratio, skeletal muscle mass, skeletal muscle mass index) were evaluated with the body analysis system device (Polosmart PSC12 Prolife) and dietary habits (meat/fish consumption, legumes consumption, egg consumption, milk/dairy product consumption and liquid consumption) were evaluated with questions created by the researchers. In the comparison of independent group differences, the Independent Samples T Test was used when the parametric test assumptions were met, and the Mann Whitney U test was used when the parametric test assumptions were not met.. Results: When comparing body compositions, there was a significant difference in skeletal muscle mass (p=0.001) and skeletal muscle mass index (p=0.002) in favor of the healthy group; but body mass index and body fat ratios were similar (p>0.05). When comparing the dietary habits, milk/dairy product (p=0.008), meat/fish (p=0.001), legumes (p=0.001) and liquid (p=0.046) consumptions were higher in healthy group; but egg consumption was similar (p>0.05) Conclusion: The patients with RA had less muscle mass, lower skeletal muscle mass index scores, and worse nutritional levels compared to healthy controls. In the light of these results, we recommend that patients with RA receive support from professional centers regulating dietary habits, as well as exercise methods that increase muscle mass.
- 31 August 2023
- Published by Bulent Evcevit University in Turkish Journal of Diabetes and Obesity
- Vol. 7 (2) , 175-181
Open AccessInvestigation of Body Compositions and Dietary Habits of Patients with Rheumatoid Arthritis: A Case Control Study
Aim: The aim of this study was to investigate the body composition and dietary habits of patients with Rheumatoid Arthritis (RA) and to compare them with healthy controls. Material and Methods: 64 participants (RA n=32 and mean age: 55.2±1.5 years; Healthy Group n=32 and mean age: 54.5±1.5 years) were included in the study. Body compositions (body mass index, body fat ratio, skeletal muscle mass, skeletal muscle mass index) were evaluated with the body analysis system device (Polosmart PSC12 Prolife) and dietary habits (meat/fish consumption, legumes consumption, egg consumption, milk/dairy product consumption and liquid consumption) were evaluated with questions created by the researchers. In the comparison of independent group differences, the Independent Samples T Test was used when the parametric test assumptions were met, and the Mann Whitney U test was used when the parametric test assumptions were not met.. Results: When comparing body compositions, there was a significant difference in skeletal muscle mass (p=0.001) and skeletal muscle mass index (p=0.002) in favor of the healthy group; but body mass index and body fat ratios were similar (p>0.05). When comparing the dietary habits, milk/dairy product (p=0.008), meat/fish (p=0.001), legumes (p=0.001) and liquid (p=0.046) consumptions were higher in healthy group; but egg consumption was similar (p>0.05) Conclusion: The patients with RA had less muscle mass, lower skeletal muscle mass index scores, and worse nutritional levels compared to healthy controls. In the light of these results, we recommend that patients with RA receive support from professional centers regulating dietary habits, as well as exercise methods that increase muscle mass.